Search

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
Community Letter: Update on FDA Guidance and Plans to Submit sNDAs